Large Unmet Clinical Needs in Stroke, Traumatic Brain Injury (TBI)/Concussion and Age-related Macular Degeneration (AMD) 

Limited options exist for patient with ischemic stroke, TBI/concussions and dry-AMD

Investigational medical device not cleared for human use

As there are no approved TBI therapies, current standard is 'rest.' Repeat TBI (concussions) leads to cognitive impairment and other neurodegenerative diseases.

With nearly 4 million annual cases of TBI in the USA, our novel approach, intranasal delivery of elovanoids, addresses a large unmet clinical need.

Stroke (ischemic)

Traumatic Brain Injury (TBI)

Age-related Macular Degeneration (AMD)

Current therapy for ischemic stroke is thrombolysis (tPA) and mechancal thrombectomy. 

However, only 10% of all ischemic stroke patients (795,000 patients in US) currently undergo thrombectomy, which has become the standard of care since 2015. Of these patients, at best 40-50% are helped with this approach. Additionally, many are turned down for not having sufficient ‘salvageable’ brain tissue (penumbra).

AMD is #1 cause of blindness in Caucasians over the age of 65 in the USA (~11 million).

For dry AMD (85-90% of all AMD), there is no treatment except vitamins, which slow it down marginally – at best.

Currently, only the neovascular part of AMD ('wet') can be treated but not the neurodegenerative part of AMD ('dry'), that affects the majority of AMD patients.

No current therapy for TBI (concussion) except 'rest.'

There is no current therapy that can halt or improve vision in dry AMD

Few effective options exists for patients with ischemic stroke and most do not receive it

Use of elovanoids for other neurodegenerative diseases with no current therapies, such as Alzheimer's, Parkinson's and other neurodegenerative diseases

Despite decades of research, there is still no promising therapy for Alzheimer's

(Below, from our research group, left) Neurons in Alzheimer's disease and right) Degenerating dopaminergic-neurons of Parikinson's Disease)